GMP Rucaparib & Intermediates, world biggest

Rucaparib world biggest manufacturer

All from GMP plant, Document is full, COA, NMR, MSDS, HPLC, LCMS, MOA, ROS all we could supply, we keep more than 10kg in stock.

Below is Intermediates we could supply:

Rucaparib Intermediate:2913-97-5,N-(2-Oxoethyl)phthalimide, assay 99.2% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok. We keep more than 5kg in stock

Rucaparib Intermediate:850462-64-5, 5-Fluoro-2-methyl-3-nitrobenzoic acid, assay 99.2% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok. We keep more than 5kg in stock.

Rucaparib Intermediate: 5-Fluoro-2-methyl-3-nitrobenzoic acid methyl, 697739-03-0  assay 99.2% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok. We keep more than 5kg in stock.


Rucaparib Intermediate: 6-Fluoro-1H-indole-4-carboxylic acid methyl ester, 1082040-43-4   assay 99.2% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok. We keep more than 5kg in stock.

Rucaparib Intermediate: 3-(2-(phthalimido)ethyl)-6-fluoro-1H-indole-4-carboxylic acid methyl ester, 1408282-25-6   assay 99.2% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok. We keep more than 5kg in stock.

Rucaparib Intermediate: 8-fluoro-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one, 1408282-26-7  assay 99.2% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok. We keep more than 5kg in stock.


Rucaparib Intermediate: 2-bromo-8-fluoro-4,5-dihydro-1H-azepino[5,4,3-cd]indol-6(3H)-one, 283173-80-8  assay 99.2% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok. We keep more than 5kg in stock.


Rucaparib Intermediate: 4-(8-fluoro-6-oxo-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-2-yl)benzaldeyde, 283173-84-2  assay 99.2% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok. We keep more than 5kg in stock.

Rucaparib Intermediate: 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6h-pyrrolo[4,3,2-ef][2]benzazepin-6-one hydrochloride, 773059-19-1  assay 99.2% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok. We keep more than 5kg in stock.

Rucaparib Intermediate: 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one, 283173-50-2 , assay 99.2% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok. We keep more than 5kg in stock.

Rucaparib CAS #: 283173-50-2 (free base) , assay 99.2% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok. We keep more than 5kg in stock.

Rucaparib CAS #: 459868-92-9 (phosphate)  , assay 99.2% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok. We keep more than 5kg in stock.

 1859053-21-6 (Rucaparib camsylate)   , assay 99.2% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok. We keep more than 5kg in stock.



Related CAS #: 283173-50-2 (free base)   459868-92-9 (phosphate)   1859053-21-6 (Rucaparib camsylate)  

Rucaparib is a tricyclic indole poly(ADP-Ribose) polymerase (PARP1) inhibitor with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Rucaparib selectively binds to PARP1 and inhibits PARP1-mediated DNA repair, thereby enhancing the accumulation of DNA strand breaks and promoting genomic instability and apoptosis.

2017 China CPHI: E1M35

EOS Med Chem, Medchem is Big

執大象，天下往，往而無害，安平泰

網址: www.eosmedchem.com 

労働時間: Beijing Time 4:00AM~11:00PM

郵箱: info@eosmedchem.com ; eosmedchem@gmail.com 

辦公室: 0086-531-69905422-806(直通)

攜帶番號 & WhatsApp & Wechat: +8618653174435

住所: Diaozhen Chemical Industrial Park, Jinan City, China

Skype: willgutian

QQ: 2393923585

Name: Rucaparib free base 
CAS#: 283173-50-2 (free base) 
Chemical Formula: C19H18FN3O 
Exact Mass: 323.1434 
Molecular Weight: 323.3714 
Elemental Analysis: C, 70.57; H, 5.61; F, 5.88; N, 12.99; O, 4.95

  
Synonym: Rucaparib free base, AG-14447; AG 14447; AG14447; Rubraca.
IUPAC/Chemical Name: 8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one
InChi Key: HMABYWSNWIZPAG-UHFFFAOYSA-N
InChi Code: InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)
SMILES Code: O=C1NCCC2=C(C3=CC=C(CNC)C=C3)NC4=C2C1=CC(F)=C4

1: Parrish KE, Cen L, Murray J, Calligaris D, Kizilbash S, Mittapalli RK, Carlson BL, Schroeder MA, Sludden J, Boddy AV, Agar NY, Curtin NJ, Elmquist WF, Sarkaria JN. Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. Mol Cancer Ther. 2015 Dec;14(12):2735-43. doi: 10.1158/1535-7163.MCT-15-0553. PubMed PMID: 26438157; PubMed Central PMCID: PMC4674360.
2: McCrudden CM, O'Rourke MG, Cherry KE, Yuen HF, O'Rourke D, Babur M, Telfer BA, Thomas HD, Keane P, Nambirajan T, Hagan C, O'Sullivan JM, Shaw C, Williams KJ, Curtin NJ, Hirst DG, Robson T. Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself. PLoS One. 2015 Feb 17;10(2):e0118187. doi: 10.1371/journal.pone.0118187. PubMed PMID: 25689628; PubMed Central PMCID: PMC4331495.
3: Murray J, Thomas H, Berry P, Kyle S, Patterson M, Jones C, Los G, Hostomsky Z, Plummer ER, Boddy AV, Curtin NJ. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. Br J Cancer. 2014 Apr 15;110(8):1977-84. doi: 10.1038/bjc.2014.91. PubMed PMID: 24556618; PubMed Central PMCID: PMC3992512.
4: Durmus S, Sparidans RW, van Esch A, Wagenaar E, Beijnen JH, Schinkel AH. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699). Pharm Res. 2015 Jan;32(1):37-46. doi: 10.1007/s11095-014-1442-z. PubMed PMID: 24962512.
5: Falzacappa MV, Ronchini C, Faretta M, Iacobucci I, Di Rorà AG, Martinelli G, Meyer LH, Debatin KM, Orecchioni S, Bertolini F, Pelicci PG. The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias. Mol Cancer Ther. 2015 Apr;14(4):889-98. doi: 10.1158/1535-7163.MCT-14-0276. PubMed PMID: 25667168.
6: Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong HM, Dandekar S, Udar N, Jänicke F, Los G, Slamon DJ, Konecny GE. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Mol Cancer Ther. 2013 Jun;12(6):1002-15. doi: 10.1158/1535-7163.MCT-12-0813. PubMed PMID: 23729402; PubMed Central PMCID: PMC3963026.
7: Wilson RH, Evans TJ, Middleton MR, Molife LR, Spicer J, Dieras V, Roxburgh P, Giordano H, Jaw-Tsai S, Goble S, Plummer R. A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. Br J Cancer. 2017 Feb 21. doi: 10.1038/bjc.2017.36. [Epub ahead of print] PubMed PMID: 28222073.
8: Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017 Jan;18(1):75-87. doi: 10.1016/S1470-2045(16)30559-9. PubMed PMID: 27908594.
9: Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer. 2016 Mar 29;114(7):723-30. doi: 10.1038/bjc.2016.41. PubMed PMID: 27002934; PubMed Central PMCID: PMC4882768.
10: Wang DD, Li C, Sun W, Zhang S, Shalinsky DR, Kern KA, Curtin NJ, Sam WJ, Kirkpatrick TR, Plummer R. PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib. Clin Pharmacol Drug Dev. 2015 Mar;4(2):89-98. doi: 10.1002/cpdd.176. PubMed PMID: 27128213.
11: Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, Morris J, Teicher B, Doroshow JH, Pommier Y. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2014 Feb;13(2):433-43. doi: 10.1158/1535-7163.MCT-13-0803. PubMed PMID: 24356813; PubMed Central PMCID: PMC3946062.
12: Rucaparib Approved for Ovarian Cancer. Cancer Discov. 2017 Feb;7(2):120-121. doi: 10.1158/2159-8290.CD-NB2016-164. PubMed PMID: 28057616.
13: Sparidans RW, Durmus S, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma. J Pharm Biomed Anal. 2014 Jan;88:626-9. doi: 10.1016/j.jpba.2013.10.016. PubMed PMID: 24216281.
14: Genomic LOH May Predict Rucaparib Response in Ovarian Cancer. Cancer Discov. 2017 Jan;7(1):OF8. doi: 10.1158/2159-8290.CD-RW2016-230. PubMed PMID: 27940438.
15: Jenner ZB, Sood AK, Coleman RL. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncol. 2016 Jun;12(12):1439-56. doi: 10.2217/fon-2016-0002. PubMed PMID: 27087632; PubMed Central PMCID: PMC4976841.
16: Plummer R, Lorigan P, Steven N, Scott L, Middleton MR, Wilson RH, Mulligan E, Curtin N, Wang D, Dewji R, Abbattista A, Gallo J, Calvert H. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol. 2013 May;71(5):1191-9. doi: 10.1007/s00280-013-2113-1. PubMed PMID: 23423489.
17: Nile DL, Rae C, Hyndman IJ, Gaze MN, Mairs RJ. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma. BMC Cancer. 2016 Aug 11;16:621. doi: 10.1186/s12885-016-2656-8. PubMed PMID: 27515310; PubMed Central PMCID: PMC4982014.
18: McCormick A, Donoghue P, Dixon M, O'Sullivan R, O'Donnell RL, Murray J, Kaufmann A, Curtin NJ, Edmondson RJ. Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib. Clin Cancer Res. 2016 Oct 4. doi: 10.1158/1078-0432.CCR-16-0564. [Epub ahead of print] PubMed PMID: 27702817.
19: Shen Y, Aoyagi-Scharber M, Wang B. Trapping Poly(ADP-Ribose) Polymerase. J Pharmacol Exp Ther. 2015 Jun;353(3):446-57. doi: 10.1124/jpet.114.222448. PubMed PMID: 25758918.
20: Anwar M, Aslam HM, Anwar S. PARP inhibitors. Hered Cancer Clin Pract. 2015 Jan 17;13(1):4. doi: 10.1186/s13053-014-0024-8. PubMed PMID: 25606064; PubMed Central PMCID: PMC4300021.

Sugammadex sodium CAS:343306-79-6, intermediates and Sugammadex Impurity, NMR, HPLC 99%+, LCMS, COA and ROS is Ok.

Sugammadex sodium CAS:343306-79-6:

NMR, HPLC 99%+, LCMS, COA and ROS is Ok, stock more than 5KG.

Name: Sugammadex sodium 

CAS NO.: 343306-79-6 (sodium salt) 

Chemical Formula: C72H104Na8O48S8 

Molecular Weight: 2177.9742 

Elemental Analysis: C, 39.71; H, 4.81; Na, 8.44; O, 35.26; S, 11.78

Sugammadex CAS:343306-71-8:

NMR, HPLC 99%+, LCMS, COA and ROS is Ok, stock more than 5KG.

Name: Sugammadex 

CAS NO.: 343306-71-8 (free form) 

Chemical Formula: C72H112O48S8 

Exact Mass: 2000.4089 

Molecular Weight: 2002.12 

Elemental Analysis: C, 43.19; H, 5.64; O, 38.36; S, 12.81

Sugammadex sodium Intermediates 53784-84-2, stock more than 5kg, HPLC, HNMR, COA, MSDS, ROS is ok.

Sugammadex sodium Intermediates 168296-33-1, stock more than 5kg, HPLC, HNMR, COA, MSDS, ROS is ok.

Sugammadex sodium Intermediates 173094-60-5, stock more than 5kg, HPLC, HNMR, COA, MSDS, ROS is ok.

Sugammadex Impurity List:

REFERENCES

1: Takazawa T, Mitsuhata H, Mertes PM. Sugammadex and rocuronium-induced anaphylaxis. J Anesth. 2016 Apr;30(2):290-7. doi: 10.1007/s00540-015-2105-x. Epub 2015 Dec 8. Review. PubMed PMID: 26646837; PubMed Central PMCID: PMC4819478.

2: Abad-Gurumeta A, Ripollés-Melchor J, Casans-Francés R, Espinosa A, Martínez-Hurtado E, Fernández-Pérez C, Ramírez JM, López-Timoneda F, Calvo-Vecino JM; Evidence Anaesthesia Review Group. A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade. Anaesthesia. 2015 Dec;70(12):1441-52. doi: 10.1111/anae.13277. Review. PubMed PMID: 26558858.

3: Ledowski T. Sugammadex: what do we know and what do we still need to know? A review of the recent (2013 to 2014) literature. Anaesth Intensive Care. 2015 Jan;43(1):14-22. Review. PubMed PMID: 25579285.

4: Partownavid P, Romito BT, Ching W, Berry AA, Barkulis CT, Nguyen KP, Jahr JS. Sugammadex: A Comprehensive Review of the Published Human Science, Including Renal Studies. Am J Ther. 2015 Jul-Aug;22(4):298-317. doi: 10.1097/MJT.0000000000000103. Review. PubMed PMID: 25299638.

5: Jahr JS, Miller JE, Hiruma J, Emaus K, You M, Meistelman C. Sugammadex: A Scientific Review Including Safety and Efficacy, Update on Regulatory Issues, and Clinical Use in Europe. Am J Ther. 2015 Jul-Aug;22(4):288-97. doi: 10.1097/MJT.0000000000000092. Review. PubMed PMID: 25299637.

6: de Boer HD, Shields MO, Booij LH. Reversal of neuromuscular blockade with sugammadex in patients with myasthenia gravis: a case series of 21 patients and review of the literature. Eur J Anaesthesiol. 2014 Dec;31(12):715-21. doi: 10.1097/EJA.0000000000000153. Review. PubMed PMID: 25192270.

7: Tsur A, Kalansky A. Hypersensitivity associated with sugammadex administration: a systematic review. Anaesthesia. 2014 Nov;69(11):1251-7. doi: 10.1111/anae.12736. Epub 2014 May 22. Review. PubMed PMID: 24848211.

8: Luxen J, Trentzsch H, Urban B. [Rocuronium and sugammadex in emergency medicine: requirements of a muscle relaxant for rapid sequence induction]. Anaesthesist. 2014 Apr;63(4):331-7. doi: 10.1007/s00101-014-2303-1. Review. German. PubMed PMID: 24595442.

9: Fuchs-Buder T, Meistelman C, Raft J. Sugammadex: clinical development and practical use. Korean J Anesthesiol. 2013 Dec;65(6):495-500. doi: 10.4097/kjae.2013.65.6.495. Epub 2013 Dec 26. Review. PubMed PMID: 24427454; PubMed Central PMCID: PMC3888841.

10: Dubois PE, Mulier JP. A review of the interest of sugammadex for deep neuromuscular blockade management in Belgium. Acta Anaesthesiol Belg. 2013;64(2):49-60. Review. PubMed PMID: 24191526.

11: Van Gestel L, Cammu G. Is the effect of sugammadex always rapid in onset? Acta Anaesthesiol Belg. 2013;64(2):41-7. Review. PubMed PMID: 24191525.

12: Schaller SJ, Fink H. Sugammadex as a reversal agent for neuromuscular block: an evidence-based review. Core Evid. 2013;8:57-67. doi: 10.2147/CE.S35675. Epub 2013 Sep 25. Review. PubMed PMID: 24098155; PubMed Central PMCID: PMC3789633.

13: Nag K, Singh DR, Shetti AN, Kumar H, Sivashanmugam T, Parthasarathy S. Sugammadex: A revolutionary drug in neuromuscular pharmacology. Anesth Essays Res. 2013 Sep-Dec;7(3):302-6. doi: 10.4103/0259-1162.123211. Review. PubMed PMID: 25885973; PubMed Central PMCID: PMC4173552.

14: Karalapillai D, Kaufman M, Weinberg L. Sugammadex. Crit Care Resusc. 2013 Mar;15(1):57-62. Review. PubMed PMID: 23432503.

15: Øberg E, Claudius C. [Possible clinical potential in reverting muscular block with sugammadex in anaesthesia and surgery]. Ugeskr Laeger. 2013 Feb 11;175(7):428-32. Review. Danish. PubMed PMID: 23402253.

16: Della Rocca G, Di Marco P, Beretta L, De Gaudio AR, Ori C, Mastronardi P. Do we need to use sugammadex at the end of a general anesthesia to reverse the action of neuromuscular bloking agents? Position Paper on Sugammadex use. Minerva Anestesiol. 2013 Jun;79(6):661-6. Epub 2012 Nov 29. Review. PubMed PMID: 23192221.

17: Stair C, Fernandez-Bustamante A. Sugammadex, the first selective relaxant binding agent for neuromuscular block reversal. Drugs Today (Barc). 2012 Jun;48(6):405-13. doi: 10.1358/dot.2012.48.6.1813474. Review. PubMed PMID: 22745926.

18: Baldo BA, McDonnell NJ, Pham NH. The cyclodextrin sugammadex and anaphylaxis to rocuronium: is rocuronium still potentially allergenic in the inclusion complex form? Mini Rev Med Chem. 2012 Jul;12(8):701-12. Review. PubMed PMID: 22512555.

19: Fuchs-Buder T, Meistelman C, Schreiber JU. Is sugammadex economically viable for routine use. Curr Opin Anaesthesiol. 2012 Apr;25(2):217-20. doi: 10.1097/ACO.0b013e32834f012d. Review. PubMed PMID: 22157200.

20: Baldo BA, McDonnell NJ, Pham NH. Drug-specific cyclodextrins with emphasis on sugammadex, the neuromuscular blocker rocuronium and perioperative anaphylaxis: implications for drug allergy. Clin Exp Allergy. 2011 Dec;41(12):1663-78. doi: 10.1111/j.1365-2222.2011.03805.x. Epub 2011 Jul 7. Review. PubMed PMID: 21732999.

Rolapitant HCl[914462-92-3 (HCl)],Rolapitant free base[552292-08-7 (free base)] and Intermediates, NMR, HPLC 99%+, LCMS, Stock more than 1KG.

Rolapitant HCl[914462-92-3 (HCl)]
Rolapitant free base[552292-08-7 (free base)]
Intermediates

we are sole GMP supplier, could provide you full document, like COA, HPLC, HNMR, MSDS, ROS.NMR, HPLC 99%+, LCMS is ok, pls kindly check:

Rolapitant HCl[914462-92-3 (HCl)]:

Name: Rolapitant HCl 

CAS#: 914462-92-3 (HCl) 

Chemical Formula: C25H27ClF6N2O2 

Exact Mass: 

Molecular Weight: 536.94 

Elemental Analysis: C, 55.92; H, 5.07; Cl, 6.60; F, 21.23; N, 5.22; O, 5.96

TECHNICAL DATA

Appearance: Solid powder

Purity: >98%+

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term 

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code: 293490

Rolapitant intermediate 552293-34-2, stock more than 1kg, HPLC, HNMR, COA, MSDS, ROS is ok.

Rolapitant intermediate 552293-37-5, stock more than 1kg, HPLC, HNMR, COA, MSDS, ROS is ok.

Rolapitant intermediate 552293-91-1, stock more than 1kg, HPLC, HNMR, COA, MSDS, ROS is ok.

Rolapitant intermediate 552293-48-8, stock more than 1kg, HPLC, HNMR, COA, MSDS, ROS is ok.

Rolapitant intermediate 552293-34-2, stock more than 1kg, HPLC, HNMR, COA, MSDS, ROS is ok.

Rolapitant intermediate 873947-63-8, stock more than 1kg, HPLC, HNMR, COA, MSDS, ROS is ok.

Rolapitant intermediate 1065272-03-8, stock more than 1kg, HPLC, HNMR, COA, MSDS, ROS is ok.

Rolapitant intermediate 1065272-06-1, stock more than 1kg, HPLC, HNMR, COA, MSDS, ROS is ok.

  Rolapitant intermediate 1214741-17-9, stock more than 1kg, HPLC, HNMR, COA, MSDS, ROS is ok.

 Rolapitant intermediate 1214741-14-6, stock more than 1kg, HPLC, HNMR, COA, MSDS, ROS is ok.

Rolapitant intermediate 1214741-13-5, stock more than 1kg, HPLC, HNMR, COA, MSDS, ROS is ok.

Rolapitant intermediate 1214741-21-5, stock more than 1kg, HPLC, HNMR, COA, MSDS, ROS is ok.

Rolapitant intermediate 1178515-20-2, stock more than 1kg, HPLC, HNMR, COA, MSDS, ROS is ok.

2017 China CPHI: E1M35

EOS Med Chem, Medchem is Big

執大象，天下往，往而無害，安平泰

網址: www.eosmedchem.com 

労働時間: Beijing Time 4:00AM~11:00PM

郵箱: info@eosmedchem.com ; eosmedchem@gmail.com 

辦公室: 0086-531-69905422-806(直通)

攜帶番號 & WhatsApp & Wechat: +8618653174435

住所: Diaozhen Chemical Industrial Park, Jinan City, China

Skype: willgutian

QQ: 2393923585

Ezutromid, 945531-77-1 , NMR, HPLC 99%+, LCMS, COA and ROS, more than 1KG in stock.

Ezutromid, 945531-77-1 , NMR, HPLC 99%+, LCMS, COA and ROS,pls kindly check.

Name: Ezutromid 

CAS#: 945531-77-1 

Chemical Formula: C19H15NO3S 

Exact Mass: 337.07726 

Molecular Weight: 337.39 

Elemental Analysis: C, 67.64; H, 4.48; N, 4.15; O, 14.23; S, 9.50

Description: Ezutromid, also known as BMN-195 and SMTC-1100, is a first orally bioavailable utrophin's translation modulator. Duchenne muscular dystrophy (DMD) is a lethal, progressive muscle wasting disease caused by a loss of sarcolemmal bound dystrophin, which results in the death of the muscle fibers leading to the gradual depletion of skeletal muscle.

Name: Ezutromid 

CAS#: 945531-77-1 

Chemical Formula: C19H15NO3S 

Exact Mass: 337.07726 

Molecular Weight: 337.39 

Elemental Analysis: C, 67.64; H, 4.48; N, 4.15; O, 14.23; S, 9.50

Synonym: BMN-195; BMN 195; BMN195; SMTC-1100; SMTC1100; SMTC 1100; VOX-C1100; Ezutromid

IUPAC/Chemical Name: 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole

InChi Key: KSGCNXAZROJSNW-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H15NO3S/c1-2-24(21,22)16-9-10-18-17(12-16)20-19(23-18)15-8-7-13-5-3-4-6-14(13)11-15/h3-12H,2H2,1H3

SMILES Code: O=S(C1=CC=C(OC(C2=CC=C3C=CC=CC3=C2)=N4)C4=C1)(CC)=O

TECHNICAL DATA

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code: 293490

2017 China CPHI: E1M35

EOS Med Chem, Medchem is Big

執大象，天下往，往而無害，安平泰

網址: www.eosmedchem.com 

労働時間: Beijing Time 4:00AM~11:00PM

郵箱: info@eosmedchem.com ; eosmedchem@gmail.com 

辦公室: 0086-531-69905422-806(直通)

攜帶番號 & WhatsApp & Wechat: +8618653174435

住所: Diaozhen Chemical Industrial Park, Jinan City, China

Skype: willgutian

QQ: 2393923585